Background
==========

Acute lymphoblastic leukemia (ALL) originates from an expansion of monoclonal malignant T or B lymphoid cells and can occur at any age, with peak incidence at 2--5 years of age \[[@b1-medscimonit-21-740]\]. The etiology of ALL is complex; it is considered to be associated with both endogenous and exogenous factors. Confirmed risk factors include congenital genetic disorders (e.g., Down syndrome, neurofibromatosis, Fanconi's anemia) and adverse environmental exposures (e.g., ionizing radiation, benzene). However, these risk factors only account for less than 10% of ALL patients \[[@b2-medscimonit-21-740]\], leaving most of the patients with still unknown causes.

With the advent of the genome-wide association study (GWAS) era, many researchers began to focus on genetic variability in drug metabolism, DNA repair, and cell-cycle checkpoints that may interact with environmental, dietary, maternal, and other external factors to affect leukemogenesis. Currently, it has been determined that variations of the genes RID5B, IKZF1, CEBPA, and CDKN2A/B are associated with increased susceptibility to ALL. However, the number of confirmed genetic risk factors is still limited, with many remaining to be identified \[[@b3-medscimonit-21-740]--[@b5-medscimonit-21-740]\].

Methylenetetrahydrofolate reductase (MTHFR) is the most critical enzyme in the folate metabolism \[[@b6-medscimonit-21-740],[@b7-medscimonit-21-740]\], catalyzing irreversible conversion of 5,10-methylenetetrahydrofolate (5,10-MTHF) to 5-methyltetrahydrofolate (5-MTHF), which is the predominant circulating form of folate. 5,10-MTHF is the intracellular coenzyme form of folate and is required for conversion of uridylate to thymidylate, which inhibits misincorporation of uridylate into DNA. Thus, folate is an important factor in DNA synthesis. In addition, MTHFR causes methylation of homocysteine into methionine, leading to methylation of DNA. Many studies have reported that aberrant DNA methylation plays important roles in the pathogenesis of many hematological malignancies through regulation of gene transcription and imprinting \[[@b8-medscimonit-21-740]--[@b13-medscimonit-21-740]\].

MTHFR gene is localized on chromosome 1p36.3 \[[@b14-medscimonit-21-740]\] and is highly polymorphic. The variant genotypes result in decreased MTHFR enzyme activity. Decreased MTHFR activity may result in mistakes during DNA replication, leading to disturbance in 5,10-MTHF metabolism, which is essential for DNA methylation, repair, and synthesis. *MTHFR C677T* and *A1298C*, the 2 most important polymorphisms in the *MTHFR* gene, contribute to the reduction of enzyme activity \[[@b15-medscimonit-21-740]\]. The *MTHFR C677T,* which has been studied extensively, involves a cytosine-to-thymine substitution at position 677, a consequence of transformation from an alanine to a valine in the enzyme. This change leads to reduced enzyme activity, and individuals heterozygous (677CT) or homozygous (677TT) for this variant had enzyme activity reduced to approximately 60% and 30%, respectively, of that of the wild type (677CC). A1298C, causing conformational changes within the MTHFR enzyme, alters enzymatic activity to a lesser extent than the C677T polymorphism does \[[@b16-medscimonit-21-740],[@b17-medscimonit-21-740]\].

Previous studies investigated the association between MTHFR C677T polymorphism and ALL risk. However, findings from these studies were conflicting. Some studies \[[@b7-medscimonit-21-740],[@b18-medscimonit-21-740]--[@b21-medscimonit-21-740]\] concluded that MTHFR C677T polymorphism was associated with a reduced ALL risk, some \[[@b22-medscimonit-21-740]--[@b26-medscimonit-21-740]\] indicated insignificant associations between the gene and ALL risk, and others \[[@b27-medscimonit-21-740]\] reported an increased ALL risk with MTHFR C677T. Likewise, many meta-analyses \[[@b28-medscimonit-21-740]--[@b36-medscimonit-21-740]\] addressing this association also arrived at inconsistent conclusions.

For independent case-control studies, this inconsistency may be attributed partly to a limited sample size in some, with insufficient statistical power to demonstrate a significant association; they also involved different populations \[[@b29-medscimonit-21-740]\] and adopted different sampling strategies. For meta-analyses, different searching strategies and inclusion criteria might have resulted in different studies included, leading to different conclusions.

There have been many recent case-control studies \[[@b22-medscimonit-21-740],[@b23-medscimonit-21-740],[@b27-medscimonit-21-740],[@b37-medscimonit-21-740]--[@b39-medscimonit-21-740]\] since the previously published meta-analyses \[[@b28-medscimonit-21-740]--[@b33-medscimonit-21-740]\]. This new evidence necessitates reassessment of the association between MTHFR C677T polymorphism and ALL risk, as performed in this updated meta-analysis. We hope that this meta-analysis of the most comprehensive literature addressing the association will yield more convincing evidence to determine the role of MTHFR C677T polymorphism in ALL risk.

Material and Methods
====================

Literature search
-----------------

A systematic search was conducted by 2 independent authors to identify studies on the association between MTHFR C677T polymorphism and ALL risk. Search term "((methylenetetrahydrofolate reductase) OR (MTHFR gene)) AND (polymorphism OR genetics) AND (acute lymphoblastic leukemia)" was used in 3 electronic databases (PubMed, Cochrane Library, and Wanfang Data) from inception to 31^st^ Dec, 2013. The references of recently published meta-analyses \[[@b28-medscimonit-21-740]--[@b33-medscimonit-21-740]\] were also checked. There was no restriction of publication language.

Inclusion and exclusion criteria
--------------------------------

The studies included for the present meta-analysis fulfilled the following criteria: (a) case-control design, (b) investigating the association between MTHFR C677T polymorphism and ALL risk, either in adult or in childhood, and (c) published reports providing sufficient data to calculate the odds ratio (OR) and its 95% confidence interval (CI). The exclusion criteria were: (a) not a case-control design, (b) not providing effective data, or (c) duplicated reports from the same group of patients.

Study identification
--------------------

Two authors independently screened titles of all studies retrieved. The abstract of any study that was potentially relevant to the topic was reviewed. The full text was obtained if inadequate information was acquired from the abstract. The corresponding author was consulted for the final decision if any disagreement on eligibility existed between the first 2 reviewers.

Data extraction
---------------

Two authors participated in data extraction independently. Disagreement was resolved by discussion and the corresponding author's opinion was asked for when necessary. Data were collected from all studies available for meta-analysis and information on general characteristics of the eligible studies and patients.

Outcomes for meta-analysis
--------------------------

The association between MTHFR C677T polymorphism and ALL risk was evaluated using the following 5 models: allele contrast (T *vs.* C), additive model (TT *vs.* CC), recessive model (TT *vs.* CC+CT), dominant model (TT+CT *vs.* CC), and heterozygote *vs.* wild-type homozygous (CT *vs.* CC) \[[@b32-medscimonit-21-740],[@b40-medscimonit-21-740]\].

The outcomes included results of the above 5 models for overall populations and those for subgroup analyses stratified by age (children and adults, the age cut-off values for children and adult complied with the studies included) and ethnicity (Asian and Caucasian).

Statistical analysis
--------------------

Statistical heterogeneity was evaluated using I^2^ statistics \[[@b41-medscimonit-21-740]\], which can be calculated from basic results obtained from a typical meta-analysis as I^2^=100% × (Q--df)/Q, where Q is Cochrane's heterogeneity statistic and df is the degrees of freedom \[[@b42-medscimonit-21-740]\]. An I^2^ value of 0% represents no heterogeneity, with values of 25%, 50%, 75%, or more represent low, moderate, high, and extreme heterogeneity, respectively. For outcomes of heterogeneity, when *P*\>0.05, a fixed-effects model was used for analyses. Otherwise, a random-effects model was adopted for *P*≤0.05. In this study, pooled odd ratios (OR) and their 95% confidence intervals (CI) from all eligible studies were used to assess the strength for the association between MTHFR C677T polymorphism and ALL risk according to the 5 models. The potential for publication bias was estimated by Begg's test (funnel plot method) and Egger's linear regression test (*P*≤0.05 indicated a statistically significant publication bias) \[[@b43-medscimonit-21-740]\].

The meta-analysis was performed using Review Manager 5.2 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012) for outcome measures. A *P* value of ≤0.05 was considered statistically significant. The publication bias analysis was performed using Stata software version 12.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Study selection and characteristics
-----------------------------------

The search process and search outcomes are listed in [Figure 1](#f1-medscimonit-21-740){ref-type="fig"}. A total of 179 potentially relevant studies were identified. After the titles, abstracts, and full texts were screened and reviewed, 51 published studies \[[@b7-medscimonit-21-740],[@b18-medscimonit-21-740]--[@b27-medscimonit-21-740],[@b37-medscimonit-21-740]--[@b39-medscimonit-21-740],[@b44-medscimonit-21-740]--[@b80-medscimonit-21-740]\] with a total of 7892 cases and 14 280 controls met all the inclusion criteria. Of all the eligible studies, 41 were published in English and 10 were in Chinese. Information about general characteristics of the eligible studies and patients are listed in [Table 1](#t1-medscimonit-21-740){ref-type="table"}.

Meta-analysis outcomes
----------------------

### Outcomes for overall populations

As shown in [Table 2](#t2-medscimonit-21-740){ref-type="table"}, no significant associations were identified in the allele contrast model \[OR 0.92, 95% CI (0.84, 1.01), *P*=0.08\], additive model \[OR 0.87, 95% CI (0.73, 1.05), *P*=0.15\], or recessive model \[OR 0.87, 95% CI (0.73, 1.05), *P*=0.15\]. However, statistically significant associations were found in the dominant model \[OR 0.89, 95% CI (0.79, 1.00), *P*=0.04\] ([Table 2](#t2-medscimonit-21-740){ref-type="table"}) and the CT *vs.* CC model \[OR 0.89, 95% CI (0.80, 1.00), *P*=0.05\] ([Table 2](#t2-medscimonit-21-740){ref-type="table"}).

### Outcomes for subgroup analyses stratified by age

A total of 35 studies investigated the association in children. Results revealed insignificant associations between MTHFR C677T polymorphism and ALL risk in all 5 models \[Allele contrast model (*P*=0.09), additive model (*P*=0.13), recessive model (*P*=0.34), dominant model (*P*=0.07), CT *vs.* CC model (*P*=0.11)\] ([Table 2](#t2-medscimonit-21-740){ref-type="table"}).

Nine studies reported the association in adults. Similarly, none of the 5 models revealed significant associations between MTHFR C677T polymorphism and ALL risk \[Allele contrast model (*P*=0.57), additive model (*P*=0.47), recessive model (*P*=0.63), dominant model (*P*=0.57), CT *vs.* CC model (*P*=0.40)\] ([Table 2](#t2-medscimonit-21-740){ref-type="table"}).

### Outcomes for subgroup analyses stratified by ethnicity

Results of 26 studies showed no significant associations between MTHFR C677T polymorphism and ALL risk in Asian populations \[Allele contrast model (*P*=0.39), additive model (*P*=0.53), recessive model (*P*=0.93), dominant model (*P*=0.22), and CT *vs.* CC model (*P*=0.15)\] ([Table 3](#t3-medscimonit-21-740){ref-type="table"}). Likewise, no significant associations were identified between MTHFR C677T polymorphism and ALL risk in Caucasian populations \[Allele contrast model (*P*=0.24), additive model (*P*=0.36), recessive model (*P*=0.56), dominant model (*P*=0.22), CT *vs.* CC model (*P*=0.29)\] ([Table 3](#t3-medscimonit-21-740){ref-type="table"}).

### Publication bias

Begg's test and Egger's linear regression test were performed to evaluate the publication bias of all eligible studies. Evaluation of publication bias for *MTHFR C677T* allele contrast model showed that the Egger test result was not significant (*P*=0.070) and the additive model also found no publication bias (*P*=0.163).

Discussion
==========

Although numerous case-control studies and meta-analyses have investigated the association between MTHFR C677T polymorphism and risk for developing ALL, no definite conclusions have been reached on the role of *MTHFR* gene in ALL. Therefore, we performed a comprehensive meta-analysis of 51 independent reports, involving a total of 7892 cases and 14 280 controls, to evaluate the association. Since the power of the present analysis was based on the aggregation of published case-control studies, the findings concerning the effect of the gene under investigation can be more powerful than those by the relative individual studies. Comparisons of the C677T allele in the global populations indicate that the T allele of the C677T polymorphism is probably not be a protective factor in the susceptibility to ALL. The subgroup analyses also showed no significant effect of age or ethnicity on the role of the T allele of the C677T polymorphism in ALL.

Although many previous meta-analyses (28--36) focused on the association between MTHFR C677T polymorphism and ALL risk, conflicting conclusions derived from these studies made the role of the gene unclear. Many factors might have accounted for the disagreements. One possible reason was related to the different search strategies and databases used for the search. A reliable and convincing meta-analysis must be based on a comprehensive search of all eligible studies. To minimize selection bias, 2 measures were taken in the present study. First, we searched the Wanfang database to include all eligible studies in Chinese patients. Second, we reviewed the references in previously published meta-analyses. Consequently, the current study was based on the largest possible amount of published data, providing the most comprehensive information on the association under investigation.

In overall population analysis based on varied populations from 22 countries, insignificant differences were identified in the allele contrast model (*P*=0.08), additive model (*P*=0.15), and recessive model (*P*=0.15), but significant differences were identified in the dominant model (*P*=0.04) and CT *vs.* CC model (*P*=0.05). However, the heterogeneity among the studies included regarding the 5 models was high, mostly due to the disparity in the age and ethnicity distributions between the eligible studies. Therefore, stratified analyses were further performed on age and ethnicity to reduce the heterogeneity. In subgroup analysis stratified by age, none of the 5 models for children or for adults showed significant differences between MTHFR C677T polymorphism and ALL risk, showing the genetic variant may not be a protective factor for ALL susceptibility in childhood or in adults. However, the accurate cut-off value for children and adults was not given due to the varied definitions of the value in the studies included, which might be a source of bias and thus of high heterogeneity. In contrast, Pereira et al. \[[@b36-medscimonit-21-740]\], based on 12 studies with 2191 cases and 3437 controls, concluded that MTHFR C677T polymorphism was associated with a reduced risk of ALL for adults but not for children. Most of the subsequent meta-analyses \[[@b29-medscimonit-21-740]--[@b31-medscimonit-21-740],[@b34-medscimonit-21-740],[@b35-medscimonit-21-740]\] supported the viewpoint that MTHFR C677T polymorphism is associated with a reduced childhood ALL risk. In agreement with our findings, Wang et al. \[[@b33-medscimonit-21-740]\] found no evidence for a protective effect of MTHFR C677T polymorphism in childhood ALL. Likewise, Zintzaras et al. \[[@b28-medscimonit-21-740]\] stated that the evidence was insufficient for a definite conclusion on the association between MTHFR C677T polymorphism and ALL risk.

Similarly, subgroup analyses on ethnicity revealed insignificant associations between MTHFR C677T polymorphism and ALL risk in Asians and Caucasians. Consistent and inconsistent findings were identified regarding the ethnic difference between the present study and previously published meta-analyses. With regard to the investigations in Asian populations, Tong et al. \[[@b32-medscimonit-21-740]\] indicated that MTHFR C677T polymorphism was not associated with ALL susceptibility, which was supported by reports by Zintzaras et al. \[[@b28-medscimonit-21-740]\] and Jiang et al. \[[@b81-medscimonit-21-740]\]. However, Yan et al. \[[@b29-medscimonit-21-740]\] and Wang et al. \[[@b31-medscimonit-21-740]\] concluded that MTHFR C677T polymorphism was a protective factor in Asians. Quite different from most of the previous meta-analyses of reduced risk with MTHFR C677T polymorphism in Caucasians, we found no protective role of this gene polymorphism in Caucasians. Therefore, due to continuing controversies, more surveys are needed to reach a precise conclusion, both in Asians and Caucasians. Although the present study found no evidence for a protective effect of MTHFR C677T polymorphism in Asians or Caucasians, differences did exist among different ethnicities as Yan et al. \[[@b29-medscimonit-21-740]\] stated, like varied allele frequencies, possible gene-gene interactions from different genetic backgrounds and possible gene-environment interactions from different lifestyles.

The larger number of eligible studies in the present study may lend it sufficient power to provide convincing evidence on the association between MTHFR C677T polymorphism and ALL risk. However, the larger sample size does not mean the study is without limitations. One limitation of the present meta-analysis is the still high heterogeneity among the studies included, which was probably due to various biases during the processes of patient selection, sample testing, and outcome reporting. Another limitation was lack of evaluation of gene-gene interactions. It has been indicated that the etiology of ALL is complex \[[@b1-medscimonit-21-740]\], involving gene-gene interactions as well as gene-environment interactions. Apart from the influence of the *MTHFR* gene on ALL susceptibility, many other genes may also play a role in the development of ALL, such as *XRCC3 Thr241Met* \[[@b82-medscimonit-21-740]\], *and MTR A2756G* \[[@b83-medscimonit-21-740]\], which might have been another reason for the high heterogeneity. Therefore, future studies should focus on the effects of gene-gene interactions.

Conclusions
===========

The present study found no evidence that MTHFR C677T polymorphism plays a protective role in the development of ALL in children, adults, Asians, or Caucasians.
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###### 

General characteristics of eligible case-control studies.

  Studies                                              Period of case diagnosis   Country       Ethnicity   Cases/controls   Source of controls
  ---------------------------------------------------- -------------------------- ------------- ----------- ---------------- --------------------
  **Adult**                                                                                                                  
  Skibola 1999 \[[@b7-medscimonit-21-740]\]            Apr.1991--Dec.1996         UK            Caucasian   71/114           Population
  Deligezer 2003 \[[@b71-medscimonit-21-740]\]         Not described              Turkey        Caucasian   62/161           Not described
  Gemmati 2004 \[[@b69-medscimonit-21-740]\]           Jan.1990--Dec.2001                                                    
  Dec.1992--Dec.2001                                   Italy                      Caucasian     114/257     Population       
  Timuragaoglu 2006 \[[@b61-medscimonit-21-740]\]      Not described              Turkey        Caucasian   33/82            Population
  Chen 2006 \[[@b74-medscimonit-21-740]\]              Jan.2004--Nov.2004         China         Asian       22/157           Population
  Zhang 2007 \[[@b77-medscimonit-21-740]\]             Jan.2003--Oct.2006         China         Asian       46/80            Population
  Oh 2007 \[[@b57-medscimonit-21-740]\]                May.2001--Jan.2002         Korea         Asian       118/427          Population
  Kim 2009 \[[@b52-medscimonit-21-740]\]               Jan.1997--Dec.2006                                                    
  Jul.2004--Jan.2006                                   Korea                      Asian         107/1700    Population       
  Lv 2010 \[[@b50-medscimonit-21-740]\]                2002--2007                 China         Asian       127/182          Hospital
  **Children**                                                                                                               
  Franco 2001 \[[@b21-medscimonit-21-740]\]            Jan. 1991--Jan.2000        Brazil        Mixed       71/71            Population
  Balta 2003 \[[@b72-medscimonit-21-740]\]             Feb.2000--Feb.2002         Turkey        Caucasian   142/185          Population
  Krajinovic 2004 \[[@b68-medscimonit-21-740]\]        Aug.1988--May.2001         Canada        Caucasian   270/300          Hospital
  Jiang 2004 \[[@b75-medscimonit-21-740]\]             Oct.2001--Aug.2002         China         Asian       29/67            Population
  Schnakenberg 2005 \[[@b66-medscimonit-21-740]\]      Jul.1999--Feb.2001         Germany       Caucasian   443/379          Population
  Thirumaran 2005 \[[@b65-medscimonit-21-740]\]        1983--2003                 Germany       Caucasian   453/1448         Population
  Oliveira 2005 \[[@b67-medscimonit-21-740]\]          Not described              Portugal      Caucasian   103/111          Population
  Yu 2006 \[[@b80-medscimonit-21-740]\]                Nov.1996--Jun.2003         China         Asian       51/53            Not described
  Kim 2006 \[[@b63-medscimonit-21-740]\]               Jul.1996--Jun.2002         Korea         Asian       66/100           Population
  Reddy 2006 \[[@b62-medscimonit-21-740]\]             Sep.2003--May.2005         India         Asian       135/142          Population
  Chatzidakis 2006 \[[@b20-medscimonit-21-740]\]       1997--2004                 Greece        Caucasian   52/88            Population
  Kamel 2007 \[[@b58-medscimonit-21-740]\]             Jan.2003--Sep.2003         Egypt         Egyptians   88/311           Population
  Petra 2007 \[[@b56-medscimonit-21-740]\]             Not described              Slovenia      Caucasian   68/258           Population
  Giovannetti 2008 \[[@b54-medscimonit-21-740]\]       Not described              Indonesia     Asian       65/32            Population
  Alcasabas 2008 \[[@b55-medscimonit-21-740]\]         Jan.2001--Dec.2005         Philippines   Asian       189/394          Population
  Yang 2009 \[[@b76-medscimonit-21-740]\]              Jan.2008--Mar.2009         China         Asian       78/129           Hospital
  de Jonge 2009 \[[@b53-medscimonit-21-740]\]          Not described              Netherlands   Caucasian   245/496          Population
  Tong 2010 \[[@b18-medscimonit-21-740]\]              Jan.2007--Jun.2009         China         Asian       361/508          Population
  Yeoh 2010 \[[@b48-medscimonit-21-740]\]              1988--2008                 Singapore     Asian       318/345          Population
  Sadananda Adiga 2010 \[[@b25-medscimonit-21-740]\]   Apr.2006--Feb.2008         India         Asian       86/99            Population
  Yu 2010 \[[@b73-medscimonit-21-740]\]                Mar.2008--Feb.2010         China         Asian       45/70            Hospital
  Damnjanovic 2010 \[[@b19-medscimonit-21-740]\]       Not described              Serbia        Caucasian   78/412           Population
  Sood 2010 \[[@b49-medscimonit-21-740]\]              Not described              India         Asian       95/255           Population
  Lightfoot 2010 \[[@b26-medscimonit-21-740]\]         1991--1996                 UK            Caucasian   805/760          Population
  Karathanasis 2011 \[[@b24-medscimonit-21-740]\]      1996--2002                 Greece        Caucasian   35/48            Population
  te winkel 2011 \[[@b46-medscimonit-21-740]\]         Not described              Netherlands   Caucasian   83/147           Population
  Chan 2011 \[[@b47-medscimonit-21-740]\]              Jan.2005--Dec.2008         Singapore     Asian       185/177          Population
  Lv 2011 \[[@b78-medscimonit-21-740]\]                May.2006--Nov.2009         China         Asian       176/170          Hospital
  Nikbakht 2012 \[[@b22-medscimonit-21-740]\]          2007--2009                 India         Asian       125/100          Population
  Feng 2012 \[[@b39-medscimonit-21-740]\]              Mar.2010--Dec.2011         China         Asian       45/45            Hospital
  Azhar 2012 \[[@b23-medscimonit-21-740]\]             Jun.2002--Sep.2009         Iran          Kurdish     72/109           Population
  Zheng 2013 \[[@b37-medscimonit-21-740]\]             Jan.2003--Dec.2011         China         Asian       87/120           Hospital
  Silva 2013 \[[@b27-medscimonit-21-740]\]             Jan.2003--Dec.2009         Brazil        Mixed       144/224          Population
  Pietrzyk 2009 \[[@b51-medscimonit-21-740]\]          Jan.2004--Sep.2006         Poland        Caucasian   403/1000         Population
  Amigou 2012 \[[@b44-medscimonit-21-740]\]            2003--2004                 French        Caucasian   434/427          Population
  **Mixed**                                                                                                                  
  Chiusolo 2004 \[[@b70-medscimonit-21-740]\]          Not described              Italy         Caucasian   174/110          Population
  Hur 2006 \[[@b64-medscimonit-21-740]\]               Jan.1995--Oct.2004         Korea         Asian       89/200           Population
  Zanrosso 2006 \[[@b60-medscimonit-21-740]\]          Not described              Brazil        Mixed       165/198          Population
  Bolufer 2007 \[[@b59-medscimonit-21-740]\]           1992--2005                 Spain         Caucasian   117/331          Population
  Liu 2008 \[[@b79-medscimonit-21-740]\]               Sep.2006--Oct.2007         China         Asian       83/83            Population
  Yang 2011 \[[@b45-medscimonit-21-740]\]              Not described              China         Asian       361/367          Population
  Hussain 2012 \[[@b38-medscimonit-21-740]\]           Mar.2006--Dec.2010         India         Asian       81/251           Not described

###### 

Stratification analyses of MTHFR C677T polymorphism on ALL by age.

  C677T     Number of studies   Allele contrast (T *vs.* C)   Additive model (TT *vs.* CC)   Recessive model (TT *vs.* CC+CT)   Dominant model (TT+CT *vs.* CC)   CT *vs.* CC                                                                                                                                    
  --------- ------------------- ----------------------------- ------------------------------ ---------------------------------- --------------------------------- ------------- ---------- ------------------- ----------- ---------- ------------------- ----------- ---------- ------------------- ----------- ----------
  Total     51                  0.92 (0.84, 1.01)             \<0.00001                      **0.08**                           0.87 (0.73, 1.05)                 \<0.00001     **0.15**   0.94 (0.81, 1.10)   \<0.00001   **0.44**   0.89 (0.79, 1.00)   \<0.00001   **0.04**   0.89 (0.80, 1.00)   \<0.00001   **0.05**
  **Age**                                                                                                                                                                                                                                                                                                        
  Child     35                  0.91 (0.81, 1.01)             \<0.00001                      **0.09**                           0.84 (0.67,1.05)                  \<0.00001     **0.13**   0.91 (0.76, 1.10)   0.0005      **0.34**   0.87 (0.76, 1.01)   \<0.00001   **0.07**   0.84 (0.67, 1.04)   \<0.00001   **0.11**
  Adult     9                   0.93 (0.72, 1.20)             0.0005                         **0.57**                           0.82 (0.47, 1.42)                 0.0010        **0.47**   0.94 (0.73, 1.20)   0.007       **0.63**   0.91 (0.67, 1.24)   0.008       **0.57**   0.93 (0.71, 1.21)   0.08        **0.40**
  Mixed     7                   0.96 (0.79, 1.17)             0.03                           **0.71**                           0.95 (0.74, 1.20)                 0.008         **0.65**   1.13 (0.73, 1.76)   0.002       **0.58**   0.88 (0.74, 1.04)   0.31        **0.13**   0.84 (0.70, 1.02)   0.25        **0.08**

MTHFR -- methylenetetrahydrofolate reductase; ALL -- acute lymphoblastic leukemia; OR -- odds ratio; CI -- confidence interval.

###### 

Stratification analyses of MTHFR C677T polymorphism on ALL by ethnicity.

  C677T           Number of studies   Allele contrast (T *vs.* C)   Additive model (TT *vs.* CC)   Recessive model (TT *vs.* CC+CT)   Dominant model (TT+CT *vs.* CC)   CT *vs.* CC                                                                                                                                    
  --------------- ------------------- ----------------------------- ------------------------------ ---------------------------------- --------------------------------- ------------- ---------- ------------------- ----------- ---------- ------------------- ----------- ---------- ------------------- ----------- ----------
  **Ethnicity**                                                                                                                                                                                                                                                                                                        
  Asian           26                  0.95 (0.84, 1.07)             \<0.0001                       **0.39**                           0.92 (0.72--1.18)                 0.003         **0.53**   0.99 (0.79, 1.24)   0.005       **0.93**   0.91 (0.77, 1.06)   0.0003      **0.22**   0.89 (0.75, 1.05)   0.0006      **0.15**
  Caucasian       20                  0.92 (0.79, 1.06)             \<0.00001                      **0.24**                           0.87 (0.64--1.18)                 \<0.00001     **0.36**   0.93 (0.72, 1.20)   \<0.00001   **0.56**   0.89 (0.74, 1.07)   \<0.00001   **0.22**   0.91 (0.77, 1.08)   \<0.00001   **0.29**
  Other           5                   0.83 (0.60, 1.13)             0.01                           **0.24**                           0.67 (0.44--1.00)                 0.19          **0.05**   0.75 (0.50, 1.11)   0.60        **0.15**   0.78 (0.63, 0.97)   0.005       **0.03**   0.83 (0.54, 1.27)   0.01        **0.39**

MTHFR -- methylenetetrahydrofolate reductase; ALL -- acute lymphoblastic leukemia; OR -- odds ratio; CI -- confidence interval.
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